Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Real-World Survival Benefit of ADT plus ARPI in Frail Veterans with mHSPC - Martin Schoen
45+ min ago (505+ words) Martin Schoen reviews a VA analysis of ADT plus ARPI combination therapy in patients defined as elderly, frail, or highly comorbid using the VA Frailty Index and Charlson Comorbidity Index. Overall survival favored combination therapy across all three subgroups, with…...
The CHAMP Regimen of Cabazitaxel-Carboplatin plus Ipilimumab-Nivolumab for Aggressive Prostate Cancer - Andrew Armstrong
55+ min ago (730+ words) UroToday...
FDA Approval of Pluvicto™ for PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer - Oliver Sartor
3+ day, 1+ hour ago (844+ words) Oliver Sartor discusses the FDA approval of Pluvicto™ (lutetium-177 PSMA-617) in metastatic hormone-sensitive prostate cancer based on PSMAddition. The trial showed rPFS benefit with a strong overall survival trend when lutetium was added to ADT plus an investigator's choice ARPI,…...
The DE-ESCALATE Trial of Intermittent ADT and ARPI in Metastatic Hormone-Sensitive Prostate Cancer - Fabio Turco
3+ day, 1+ hour ago (1146+ words) UroToday...
Immune Microenvironment Heterogeneity in Low and High Gleason Localized Prostate Cancer - Aishwarya Atmakuri
3+ day, 5+ hour ago (650+ words) Aishwarya Atmakuri describes a multiplex immunofluorescence analysis of 29 radical prostatectomy specimens from treatment-naive patients comparing the immune microenvironment of low Gleason and high Gleason localized prostate cancer. High Gleason tumors showed greater immune infiltration, including elevated regulatory T-cells and M2-like…...
Urinary Tumor DNA and De-escalation of Immunotherapy in High-Risk NMIBC - Jianpeng Yu
6+ day, 1+ hour ago (562+ words) Jianpeng Yu discusses single-center data on urinary tumor DNA as a guide for deescalating systemic immunotherapy in very high-risk non-muscle-invasive bladder cancer. All enrolled patients had achieved complete response with utDNA negativity before allocation to either a short-term arm of…...
TRUCE 2 Trial of utDNA-Directed Immunotherapy Duration for High-Risk NMIBC - Zihan Xue & Yunkai Qie
5+ day, 21+ hour ago (595+ words) UroToday Ashish Kamat: Hello everybody and welcome to UroToday I'm Ashish Kamat, Urologic Oncologist in Houston, Texas, and it's a pleasure to welcome to our forum two prominent urologists all the way from Tianjin, China, Dr Xue.Today we're going…...
Discussant Perspective on Minimizing Toxicity and Maximizing Outcomes in Prostate Cancer - Catherine Handy Marshall
5+ day, 21+ hour ago (662+ words) Catherine Marshall discusses two prostate cancer oral abstracts at ASCO 2026. A-DREAM enrolled approximately 75 patients with metastatic castration-sensitive prostate cancer who achieved undetectable PSA after 18 to 24 months on treatment and then stopped therapy entirely; roughly 40% met the primary endpoint of testosterone…...
Validation of the PSA NADIR Model in the ARCHES Trial for Metastatic Prostate Cancer - Soumyajit Roy
6+ day, 19+ hour ago (752+ words) UroToday Neeraj Agarwal: Hi, my name is Dr I'm a GU medical oncologist at the University of Utah Huntsman Cancer Institute Today, I'm so pleased to have Dr Soum Roy from Case Western University, a newly minted assistant professor in…...
A Patient-Centered Toxicity Framework and Quality of Life in Adjuvant RCC - Elizabeth Nally
6+ day, 21+ hour ago (842+ words) Elizabeth Nally shares a patient-derived toxicity framework developed from interviews with kidney cancer patients and applied to IMmotion010, a global phase 3 adjuvant trial. Four categories replaced CTCAE grading, and more than 30% of grade 1-2 events were recategorized as significant or life-changing. Quality…...